These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 38844304

  • 1. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G.
    Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H.
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [Abstract] [Full Text] [Related]

  • 4. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA, Maurer TS, Li Z, Bulawa C, Fleming J, Moody AT.
    Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
    [Abstract] [Full Text] [Related]

  • 5. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 6. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
    Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    N Engl J Med; 2018 Sep 13; 379(11):1007-1016. PubMed ID: 30145929
    [Abstract] [Full Text] [Related]

  • 7. Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients.
    Ministrini S, Niederberger R, Akhmedov A, Beer G, Puspitasari YM, Franzini M, Vergaro G, Cannie DE, Elliott P, Kahr PC, Hock C, Kobza R, Toggweiler S, Lüscher TF, Camici GG, Stämpfli SF.
    Vascul Pharmacol; 2024 Sep 13; 156():107411. PubMed ID: 39029855
    [Abstract] [Full Text] [Related]

  • 8. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB, Ghode P, Joshi P.
    Mini Rev Med Chem; 2024 Sep 13; 24(6):571-587. PubMed ID: 37828667
    [Abstract] [Full Text] [Related]

  • 9. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN.
    Am J Cardiovasc Drugs; 2021 Jan 13; 21(1):113-121. PubMed ID: 33469827
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
    Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R.
    Proc Natl Acad Sci U S A; 2012 Jun 12; 109(24):9629-34. PubMed ID: 22645360
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y, Baranczak A, Helmke S, Teruya S, Horn EM, Maurer MS, Kelly JW.
    Amyloid; 2015 Jun 12; 22(3):175-80. PubMed ID: 26193961
    [Abstract] [Full Text] [Related]

  • 15. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis.
    Saro R, Allegro V, Merlo M, Dore F, Sinagra G, Porcari A.
    Heart Fail Clin; 2024 Jul 12; 20(3):343-352. PubMed ID: 38844305
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ.
    Circ Heart Fail; 2022 Jan 12; 15(1):e008193. PubMed ID: 34923848
    [Abstract] [Full Text] [Related]

  • 17. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C.
    ESC Heart Fail; 2019 Feb 12; 6(1):232-236. PubMed ID: 30478886
    [Abstract] [Full Text] [Related]

  • 18. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D, Di Stefano V, Brighina F, Galassi AR, Novo G.
    Curr Probl Cardiol; 2023 Feb 12; 48(2):101487. PubMed ID: 36336119
    [Abstract] [Full Text] [Related]

  • 19. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.
    Uemura K, Ichikawa Y, Nagai S, Nishihara Y, Todo S, Oota E, Odajima S, Takeuchi K, Kintsu M, Fukuda T, Hisamatsu E, Hirata KI, Tanaka H.
    Heart Vessels; 2024 Sep 12; 39(9):810-817. PubMed ID: 38743105
    [Abstract] [Full Text] [Related]

  • 20. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 12; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.